Fig. 1.

Flow diagram of the objective patients with unresectableHCC. Of the unresectable HCC patients who received ICI therapy at the Kindai University Hospital from January 2015 to March 2020, published 18 patients met the inclusion criteria were selected. HCC, hepatocellular carcinoma; ICIs, immune checkpoint inhibitors; PD-1, programmed cell death 1; PD-L1, programmed death ligand-1; CTLA-4, cytotoxic T-lymphocyte antigen 4; Gd-EOB-DTPA, gadolinium-ethoxybenzyl-diethylenetriamine; MRI, magnetic resonance imaging.